Amarantus Bioscience Holdings Inc (AMBS)

[Deagle]

maybe it is or maybe it ain't but it is up 33% since this morning, why :trash mouth" it? If you want to help a trader, then detail from a chart why one thinks it will go up or down that day.
If they can get things worked out, the connection to working on this skin substitute with the US Army will be a serious change once accomplished. If they really believe they have something and get funding, then AMBS will climb in value. Funding filing will turn things around. Yes, they have to get funding to get started off

Item 1.02 Termination of a Material
Definitive Agreement
On September 30, 2016,
Lonza Walkersville, Inc. (“Lonza”) informed Amarantus Bioscience Holdings, Inc. (the “Company”) that the
Manufacturing
Services Agreement dated as of July 14, 2015 between Lonza and the Company (the “MSA”) with respect to
the manufacture of the Company’s ESS product, had
been terminated by Lonza pursuant to the terms of the MSA due to lack of
payment. The Company is seeking to work with Lonza to enter into a new MSA to
provide for the initiation of its Phase 2 trial with
the US Army, subject to funding by the Company.

SAN FRANCISCO, August 8, 2016 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced the publication of a 16-subject clinical study of Engineered Skin Substitute ("ESS," or "Permaderm™") in children with life-threatening severe burns. In this study, ESS was compared with the standard of care (split-thickness autograft "AG") for treating full-thickness (dermal and epidermal layers of skin) life-threatening pediatric severe burns covering a total body surface area (TBSA) of 50% or greater. Amarantus' wholly-owned subsidiary Cutanogen Corporation is pursuing the development of ESS towards regulatory approval for the treatment of life-threatening severe burns. ESS has received orphan drug designation from the U.S. FDA in the treatment of full-thickness burns covering over 50% TBSA.